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With the growing prevalence of myopia, already at epidemic levels in some countries, there is
an urgent need for new management approaches. However, with the increasing number of
research publications on the topic of myopia control, there is also a clear necessity for
agreement and guidance on key issues, including on how myopia should be defined and how
interventions, validated by well-conducted clinical trials, should be appropriately and
ethically applied. The International Myopia Institute (IMI) reports the critical review and
synthesis of the research evidence to date, from animal models, genetics, clinical studies, and
randomized controlled trials, by more than 85 multidisciplinary experts in the field, as the
basis for the recommendations contained therein. As background to the need for myopia
control, the risk factors for myopia onset and progression are reviewed. The seven generated
reports are summarized: (1) Defining and Classifying Myopia, (2) Experimental Models of
Emmetropization and Myopia, (3) Myopia Genetics, (4) Interventions for Myopia Onset and
Progression, (5) Clinical Myopia Control Trials and Instrumentation, (6) Industry Guidelines
and Ethical Considerations for Myopia Control, and (7) Clinical Myopia Management
Guidelines.
Keywords: myopia control, myopic progression, clinical guidelines, definition, interventions
1. PREVIOUS GUIDANCE ON MYOPIA CONTROL
While eye care professionals have put forward views onhow to slow myopia progression for centuries, the first
evidence-based review to make clinical recommendations
appears to have been in 2002, based on the only 10 randomized
controlled trials to have been conducted at that time. This
report concluded that bifocal spectacle lenses and soft contact
lenses are not recommended for slowing the progression of
myopia in children, nor is the routine use of atropine eye
drops.1 Since that time, more than 170 peer-reviewed articles
on myopia control have been published, making it difficult for
clinicians to keep abreast of the latest findings and how they
should affect the optimum management of their patients. Few,
if any, professional bodies have issued documented guidance on
the treatment of myopia (in contrast to the correction of the
refractive error). While eye care practitioners from across the
globe seem concerned about the increasing levels of myopia in
their practices, especially in Asia, and report relatively high
levels of activity in controlling myopia, most still prescribe
single-vision spectacles and contact lenses to their progressing
myopes.2 Hence, there is a need for evidence-based interven-
tion strategies, informed by animal model and genetic studies,
with agreement on how myopia should be defined, validated by
well-designed and ethically applied clinical trials. The Interna-
tional Myopia Institute (IMI) reports represent the work of
more than 85 multidisciplinary experts in the field, who set out
to critically review, synthesize, and summarize the research
evidence to date (Table 1), and serve to inform both clinical
practice and future research.
2. THE IMI REPORT GENERATION PROCESS
As highlighted in the accompanying editorial, the foundation of
the IMI was an outcome of the World Health Organization–
associated global scientific meeting on Myopia, held at the
Brien Holden Vision Institute in Sydney, Australia, in 2015. As
part of the IMI’s mission to address identified key issues related
to myopia, they approached a group of experts to produce two
white papers in November 2015, one focused on Myopia
Interventions (optical, pharmaceutical, and behavioral/environ-
mental) and the other on Definitions and Classification of
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TABLE 1. International Myopia Institute (IMI) Report Subcommittee
Members
IMI – Defining and Classifying Myopia
Daniel Ian Flitcroft, MBBS, PhD
Children’s University Hospital, University College Dublin and
Dublin Institute of Technology, Dublin, Ireland
Mingguang He, MD, PhD
Centre for Eye Research Australia; Ophthalmology, Department of
Surgery, University of Melbourne, Melbourne, Australia
Jost B. Jonas, MD
Department of Ophthalmology, Medical Faculty Mannheim of the
Ruprecht-Karis-University Heidelberg, Mannheim, Germany
Monica Jong, PhD
Brien Holden Vision Institute and School of Optometry and Vision
Science, University of New South Wales, Sydney, New South
Wales, Australia
Kovin Naidoo, OD, PhD
African Vision Research Institute, University of KwaZulu-Natal,
Durban, South Africa
Kyoko Ohno-Matsui, MD, PhD
Tokyo Medical and Dental University, Tokyo, Japan
Jugnoo Rahi, MBBS, PhD
Institute of Child Health, University College London and Great
Ormond Street Hospital for Children, London, United Kingdom
Serge Resnikoff, MD, PhD
Brien Holden Vision Institute and School of Optometry and Vision
Science, University of New South Wales, Sydney, New South
Wales, Australia
Susan Vitale, PhD, MHS
National Eye Institute, National Institutes of Health, Bethesda,
Maryland, United States
Lawrence Yannuzzi, MD
The Vitreous, Retina, Macula Consultants of New York; The
LuEsther T. Mertz Retina Research Center, Manhattan Eye, Ear, and
Throat Hospital, New York, New York, United States
IMI – Experimental Models of Emmetropization and Myopia
David Troilo, PhD
SUNY College of Optometry, State University of New York, New
York, New York, United States
Earl L. Smith III, OD, PhD
College of Optometry, University of Houston, Houston, Texas,
United States
Debora Nickla, PhD
Biomedical Sciences and Disease, New England College of
Optometry, Boston, Massachusetts, United States
Regan Ashby, PhD
University of Canberra, Health Research Institute, Canberra,
Australia
Andrei Tkatchenko, MD, PhD
Department of Ophthalmology, Columbia University, New York,
New York, United States
Lisa A. Ostrin, OD, PhD
College of Optometry, University of Houston, Houston, Texas,
United States
Tim J. Gawne, PhD
College of Optometry, University of Alabama Birmingham,
Birmingham, Alabama, United States
Machelle T. Pardue, PhD
Biomedical Engineering, Georgia Tech College of Engineering,
Atlanta, Georgia, United States
Jody A. Summers, PhD
College of Medicine, University of Oklahoma, Oklahoma City,
Oklahoma, United States
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Chea-su Kee, BSc Optom, PhD
School of Optometry, The Hong Kong Polytechnic University, Hong
Kong, Special Administrative Region, China
Falk Schroedl, MD
Department of Ophthalmology and Anatomy, Paracelsus Medical
University, Salzburg, Austria
Siegfried Wahl, PhD
Institute for Ophthalmic Research, University of Tuebingen, Zeiss
Vision Science Laboratory, Tuebingen, Germany
Lyndon Jones, PhD, DSc, FCOptom
Centre for Ocular Research & Education (CORE), School of
Optometry & Vision Science, University of Waterloo, Waterloo,
Canada
IMI – Myopia Genetics
Milly S. Tedja, MD
Department of Ophthalmology, Department of Epidemiology,
Erasmus Medical Center, Rotterdam, The Netherlands
Annechien E. G. Haarman, MD
Department of Ophthalmology, Department of Epidemiology,
Erasmus Medical Center, Rotterdam, The Netherlands
CREAM Consortium
Magda A. Meester-Smoor, PhD
Department of Ophthalmology, Department of Epidemiology,
Erasmus Medical Center, Rotterdam, The Netherlands
Jaakko Kaprio, MD, PhD
Faculty of Sport and Health Sciences, University of Jyva¨skyla¨,
Jyva¨skyla¨, Finland
David A. Mackey, MD, PhD
Department of Ophthalmology, Menzies Institute of Medical
Research, University of Tasmania, Hobart, Tasmania, Australia
Jeremy Guggenheim, MCOptom, PhD
School of Optometry & Vision Sciences, Cardiff University, Cardiff,
United Kingdom
Christopher J. Hammond, MD, PhD
Section of Academic Ophthalmology, School of Life Course
Sciences, King’s College London, London, United Kingdom
Virginie J. M. Verhoeven, MD, PhD
Department of Ophthalmology, Department of Epidemiology,
Erasmus Medical Center, Rotterdam, The Netherlands
Caroline C. W. Klaver, MD, PhD
Department of Ophthalmology, Radboud University Medical Center,
Nijmegen, The Netherlands
IMI – Interventions for Myopia Onset and Progression
Christine F. Wildsoet, DipAppSci (Optom), BSci (Hons Pharm), PhD
Berkeley Myopia Research Group, School of Optometry & Vision
Science Program, University of California Berkeley, Berkeley,
California, United States
Audrey Chia Wei Lin Franzco, PhD
Singapore Eye Research Institute, Singapore National Eye Center,
Singapore
Pauline Cho, BOptom, PhD
School of Optometry, The Hong Kong Polytechnic University, Hong
Kong
Jeremy A. Guggenheim, MCOptom, PhD
School of Optometry & Vision Sciences, Cardiff University, Cardiff,
United Kingdom
Jan Roelof Polling, BoH
Department of Ophthalmology, Erasmus Medical Center,
Rotterdam, The Netherlands
Scott Read, BAppSci Optom (Hons), PhD
School of Optometry & Vision Science, Institute of Health &
Biomedical Innovation, Queensland University of Technology,
Brisbane, Queensland, Australia
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Padmaja Sankaridurg, BOptom, PhD
Brien Holden Vision Institute, School of Optometry and Vision
Science, University of New South Wales, Sydney, Australia
Seang-Mei Saw, MPH, PhD
Saw Swee Hock School of Public Health, National University of
Singapore, Singapore
Klaus Trier, MD
Trier Research Laboratories, Hellerup, Denmark
Jeff J. Walline, OD, PhD
The Ohio State University College of Optometry, Columbus, Ohio,
United States
Pei-Chang Wu, MD, PhD
Department of Ophthalmology, Kaohsiung Chang Gung Memorial
Hospital, Chang Gung University College of Medicine, Kaohsiung,
Taiwan
James S. Wolffsohn, FCOptom, PhD
Ophthalmic Research Group, Aston University, Birmingham, United
Kingdom
IMI – Clinical Myopia Control Trials and Instrumentation
James S. Wolffsohn, FCOptom, PhD
Ophthalmic Research Group, Aston University, Birmingham, United
Kingdom
Pete S. Kollbaum, OD, PhD
Indiana University, School of Optometry, Bloomington, Indiana,
United States
David A. Berntsen, OD, PhD
The Ocular Surface Institute, College of Optometry, University of
Houston, Houston, Texas, United States
David A. Atchison, DSc
School of Optometry & Vision Science, Institute of Health &
Biomedical Innovation, Queensland University of Technology,
Australia
Alexandra Benavente, MCOptom, PhD
SUNY College of Optometry, New York, New York, United States
Arthur Bradley, PhD
Indiana University, School of Optometry, Bloomington, Indiana,
United States
Hetal Buckhurst, MCOptom, PhD
School of Health Professions, Peninsula Allied Health Centre,
Plymouth University, Plymouth, United Kingdom
Michael Collins, Dip App Sc (Optom), PhD
Queensland University of Technology, Brisbane, Queensland,
Australia
Takashi Fujikado, MD, PhD
Department of Applied Visual Science, Osaka University Graduate
School of Medicine, Osaka, Japan
Takahiro Hiraoka, MD, PhD
Department of Ophthalmology, Faculty of Medicine, University of
Tsukuba, Ibaraki, Japan
Masakazu Hirota, MSc
Department of Applied Visual Science, Osaka University Graduate
School of Medicine, Osaka, Japan
Debbie Jones, FCOptom
School of Optometry & Vision Science, University of Waterloo,
Waterloo, Ontario, Canada
Nicola S. Logan, MCOptom, PhD
Ophthalmic Research Group, Aston University, Birmingham, United
Kingdom
Linda Lundstro¨m, PhD
Applied Physics, KTH Royal Institute of Technology, Stockholm,
Sweden
Scott A. Read, BAppSci Optom, PhD
School of Optometry & Vision Science, Institute of Health &
Biomedical Innovation, Queensland University of Technology,
Brisbane, Queensland, Australia
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Hidemasa Torii, MD, PhD
Department of Ophthalmology, Keio University School of Medicine,
Tokyo, Japan
Kovin Naidoo, OD, PhD
African Vision Research Institute, University of KwaZulu-Natal,
Durban, South Africa
IMI – Industry Guidelines and Ethical Considerations for
Myopia Control
Lyndon Jones, PhD, DSc, FCOptom
Centre for Ocular Research & Education (CORE), School of
Optometry & Vision Science, University of Waterloo, Waterloo,
Canada
Bjo¨rn Drobe, MSc, PhD
Essilor R&D, Vision Sciences AMERA, Center of Innovation and
Technology AMERA, Singapore, Singapore
Jose´ Manuel Gonza´lez-Me´ijome, OD, PhD
Clinical & Experimental Optometry Research Lab, Center of
Physics (Optometry), School of Science, University of Minho,
Braga, Portugal
Lyle Gray, PhD, BSc, Dip Optom
Department of Vision Sciences, Glasgow Caledonian University,
Glasgow, United Kingdom
Timo Kratzer, Dipl Phys
Carl Zeiss Vision International GmbH, Aalen, Germany
Steve Newman
Menicon Company Limited, Nagoya, Japan
Jason J. Nichols, OD, MPH, PhD
University of Alabama at Birmingham, School of Optometry,
Birmingham, Alabama, United States
Arne Ohlendorf, PhD
Carl Zeiss Vision International GmbH, Aalen, Germany
Stephanie Ramdass, OD, MS
Vision Research Institute, Michigan College of Optometry, Ferris
State University, Big Rapids, Michigan, United States
Jacinto Santodomingo-Rubido, MSc, PhD
Menicon Company Limited, Nagoya, Japan
Katrina L. Schmid, PhD
School of Optometry and Vision Science, Institute of Health and
Biomedical Innovation, Faculty of Health, Queensland University of
Technology, Brisbane, Queensland, Australia
Donald Tan, FRCS
Ophthalmology and Visual Sciences Academic Clinical Program,
Duke-National University of Singapore Medical School, Singapore
Eye Research Institute, Singapore National Eye Centre, Singapore
Kah-Ooi Tan, MBA, PhD
Brien Holden Vision Institute, Sydney, New South Wales, Australia
Fuensanta A. Vera-Diaz, OD, PhD
New England College of Optometry, Boston, Massachusetts, United
States
Yee-Ling Wong, BSc
Essilor R&D, Vision Sciences AMERA, Center of Innovation and
Technology AMERA, Singapore, Singapore
Kate L. Gifford, BAppSc (Optom), PhD
Queensland University of Technology, Brisbane, Queensland,
Australia
Serge Resnikoff, MD, PhD
Brien Holden Vision Institute, Sydney, New South Wales, Australia
IMI – Clinical Myopia Management Guidelines
Kate L. Gifford, BAppSc (Optom), PhD
Queensland University of Technology, Brisbane, Queensland,
Australia
Kathryn Richdale, OD, PhD
University of Houston, Houston, Texas, United States
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Myopia (high myopia, pathologic myopia, and myopic macular
degeneration). An IMI steering and an advisory board were
established also in November 2015 at the American Academy
of Ophthalmology meeting in Las Vegas to oversee the process.
A separate initiative at a similar time, led by James Wolffsohn
and Nicola Logan of Aston University (Birmingham, UK),
approached leading experts in the field to establish a steering
committee to put together an evidence-based global consensus
on myopia control, in particular to inform clinicians, based on
the well-established approach taken by the Tear Film and
Ocular Surface Society. The two groups agreed to bring the
initiatives together at a meeting at The Association for Research
in Vision and Ophthalmology (ARVO) in May 2016 in Seattle. It
was agreed that Earl Smith and James Wolffsohn would chair
the initiative supported by the IMI. Monica Jong from the Brien
Holden Vision Institute facilitated the entire process. In March
2017, the new white papers to accompany the original two
had been agreed on and potential chairs approached.
In developing this set of reports, the IMI has collaborated
closely with the past and present organizers of The Interna-
tional Myopia Conference (IMC), an international event that
has been in existence since 1964 and is now a biennial event
(Table 2). The IMC is devoted to promoting all aspects of
myopia research at the basic level through to translational
research and clinical myopia research, thereby bringing
together a wide range of disciplines. The attendance at the
congress reflects the diversity of persons involved in myopia-
related activities, including researchers, academics, practition-
ers, policy makers, industry representatives, and students. The
IMC started more than 50 years ago; however, it was Sek Jin
Chew in collaboration with Josh Wallman who was instru-
mental in reviving the conference in 1990. The site-hosting
organization and organizing committee change for each
meeting, thus ensuring diversity at many levels. Chew and
Wallman re-established the IMC meetings, using local organiz-
ing committees beginning in 1990, adopting the numbering
based on the original Myopia International Research Founda-
tion sponsored meetings.
Experts in the field (as identified by the IMI and IMC) were
approached for expressions of interest to contribute to one of
the reports of their choice. An inclusive approach was
adopted, while limiting the number of participants from any
one research group to ensure a balanced representation.
Discussion between the chairs resulted in report selection for
each individual, based on their expertise. The then IMI steering
board (David Friedman, Mingguang He, Jonas Jost, Ohno-
Matsui Kyoko, Kovin Naidoo [chair], Jason Nichols, Serge
Resnikoff, Earl Smith, Hugh Taylor, Christine Wildsoet, James
Wolffsohn, Tien Wong) and the chairs met at ARVO in May
2017 in Baltimore. The steering committee was responsible for
developing the specific aims and mission, along with the
strategy for these reports, and agreed on the topics, conflict of
interest policy, chairs, and committee members. The chairs
(Table 3) presented to a special session at the IMC in
Birmingham, United Kingdom, in September 2017 and the
report committee membership was expanded based on further
interest and feedback. The report committees also met to
finalize their paper’s outline and to allocate the workload
immediately after the meeting. Shortly after this meeting an
agreement was put in place to publish all the reports in a
special issue of Investigative Ophthalmology & Visual Science
(IOVS).
By early 2018, the draft report was put together from the
contributions of each committee, and authorship was deter-
mined on the basis of contribution. The draft reports were
circulated to that committee to review as a whole, to ensure all
issues were adequately addressed. In March 2018, the report
drafts were circulated to all 88 members of the IMI committees
(who came from 17 counties) for review by July. At ARVO in
May 2018 the IMI steering committee received reports from
each of the committee chairs. Reviewer comments were
received by the report chairs and addressed one by one, as
occurs in a traditional peer review of academic manuscripts, to
ensure all views were considered. Experts in the field who
work for industry were not excluded from the report
committees owing to their valuable experience, but the review
process outlined ensured no undue influence. The sponsors
contributed to publication costs of the International Myopia
Reports. The appointed harmonizer to each report (see Table
3) was then responsible for ensuring the reviewers’ comments
had been adequately addressed, that overlap between the
TABLE 1. Continued
Pauline Kang, BOptom, PhD
University of New South Wales, Sydney, New South Wales,
Australia
Thomas A. Aller, OD
University of California, Berkeley, California, United States
Carly S. Lam, BSc, PhD
The Hong Kong Polytechnic University, Hong Kong
Y. Maria Liu, OD, PhD
University of California, Berkeley, California, United States
Langis Michaud, OD, MSc
University of Montreal, Montreal, Quebec, Canada
Jeroen Mulder, BOptom, MSc
University of Applied Sciences Utrecht, Utrecht, The Netherlands
Janis B. Orr, BSc, PhD
Aston University, Birmingham, United Kingdom
Kathryn A. Rose, PhD
University of Technology Sydney, New South Wales, Australia
Kathryn J. Saunders, FCOptom, PhD
Ulster University, Londonderry, United Kingdom
Dirk Seidel, PhD
Glasgow Caledonian University, Glasgow, United Kingdom
J. Willem Tideman, MD, PhD
Erasmus Medical Centre, Rotterdam, The Netherlands
Padmaja Sankaridurg, BOptom, PhD
Brien Holden Vision Institute, School of Optometry and Vision
Science, University of New South Wales, Sydney, Australia
CREAM, the international Consortium for Refractive Error and
Myopia.
TABLE 2. Past International Myopia Conferences
1st* New York, New York, United States (1964)
2nd† Yokohama, Japan (1978)
3rd† Copenhagen, The Netherlands (1980)
2nd* San Francisco, California, United States (1984)
3rd* Rome, Italy (1986)
4th Singapore (1990)
5th Toronto, Ontario, Canada (1994)
6th Hakone, Japan (1996)
7th Taipei, Taiwan (1998)
8th Boston, Massachusetts, United States (2000)
9th Hong Kong, Guangzhou (2002)
10th Cambridge, United Kingdom (2004)
11th Singapore (2006)
12th Cairns, Australia (2008)
13th Tu¨bingen, Germany (2010)
14th Asilomar, California, United States (2013)
* Organized by the Myopia International Research Foundation.
† Independently organized by local organizing committees. (Not
recognized by the Myopia International Research Foundation.)
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reports was minimized (with appropriate cross-referencing),
and that the report styles were unified as much as possible.
The harmonizers had a meeting in August 2018 and
subsequent email communication to resolve any issues arising.
It was acknowledged that some areas of overlap would remain
where aspects were approached from a different angle (such as
crafting a clinical trial protocol as compared to clinical
guidance). The imperative of promoting myopia control as an
ethical imperative, due to the evidence-based risk of compli-
cations from higher levels of myopia and the availability of
treatments with proven effectiveness (compared to the risk of
complications from the treatment modality), was of particular
note. Hence, the reports promote open communication with
patients and their parents/guardians regarding the risk versus
benefits, such that a fully informed, joint decision on treatment
adoption can be made. Finalized harmonized reports were
submitted for publication in IOVS in October 2018.
3. BACKGROUND TO THE NEED FOR MYOPIA CONTROL
3.1 Refractive Development
From birth, eye growth continues and refractive state normally
undergoes a gradual shift toward emmetropia. In the first 6
months of life, human newborns typically have a variable, but
low hyperopic, cycloplegic refractive error with mean of
approximatelyþ2.00 diopters (D) (6SD 2.75 D), which shows
a normal distribution in the population.3–6 Emmetropization
over the subsequent 6 to 12 months of age leads to a reduction
in hyperopia, and the normal distribution of refractive errors
seen in neonates becomes more leptokurtic as the eye
matures.7 For the next several years, hyperopic refractive
error will reduce slowly such that, by 5 to 7 years of age, most
children will have a refractive error in the low hyperopic range
(plano to þ2.00 D).3,6,8,9 In populations with relatively low to
modest education levels, refractive error is likely to endure at
this level throughout the teenage and adult years.10 In some
individuals, for reasons not well understood, the refractive
error will become myopic and is likely to progress for a period
of time.
3.2 Myopia Onset
In children younger than 6 years the prevalence of myopia is
low.11–19 Even in East Asia and Singapore, where the
prevalence of myopia is considered to be alarmingly high in
young adults, most studies12,14,15,17,20–22 show a prevalence
rate of myopia in the pre–6-year-old age group to be less than
5%. In certain populations, myopia has been found in more
than 5% of children younger than 6 years, although the
prevalence rarely exceeds 10%.11,14,23 Recent studies have
reported that the incidence of myopia in this age group may be
increasing. Fan et al.23 report that the prevalence of myopia in
Hong Kong preschoolers (mean age, 4.6 6 0.9 years; range, 3–
6 years) has increased significantly from 2.3% to 6.3% over 10
years.
The incidence of myopia increases dramatically in at-risk
populations from approximately 6 years of age.24 Previous
studies have linked this change with the beginning of primary
school education, and a link between the intensity of the
education system and myopia onset has been deter-
mined.10,24,25 The annual incidence of myopia onset is
reasonably constant between the ages of approximately 7
and 15 years in Chinese populations and, by the age of 18
years, some 80% of the urban-based Han population in China is
myopic, regardless of geographic locality.17,26–28 Singapore,
Hong Kong, Taiwan, South Korea, and Japan show similar
patterns, although incidence may be higher in Singapore,
Taiwan, and Hong Kong at younger ages.29–37 A systematic
review and meta-analysis by Rudnicka et al.37 has reported an
increase of 23% in the prevalence of myopia over the last
decade among East Asians.
In Western societies and countries other than those
mentioned above, the incidence of myopia onset during
childhood years, and thus the corresponding prevalence, is
much lower.37 Most of the myopia cases identified in one study
in the United Kingdom was considered to be late onset (16
years or older).38 Figure 1 illustrates the marked difference in
prevalence between East Asian and white children from the
meta-analysis of Rudnicka et al.37 Of ethnicities reported in the
meta-analysis, populations in south Asian, black populations in
Africa, and Hispanics tended to have lower prevalence than
Western white populations, with South-East Asians, black
populations not in Africa, Middle Eastern/North African
populations, Native Hawaiians, and American Indians showing
higher prevalence than white populations, but still much lower
than East Asians.37
FIGURE 1. Modeled prevalence of myopia by age for East Asian and
white children and teenagers from a systematic review and quantitative
meta-analysis fitted to the year 2005. Graph created from data in Table
3 of Rudnicka et al.37
TABLE 3. Report Committees, Chairs, and Harmonizers
Report Subcommittee Chair(s) Harmonizer(s)
Defining and Classifying Myopia Ian Flitcroft Earl Smith
Experimental Models of Emmetropization and Myopia David Troilo & Earl Smith Lyndon Jones
Myopia Genetics Caroline Klaver Earl Smith
Interventions for Myopia Onset and Progression Christine Wildsoet James Wolffsohn
Clinical Myopia Control Trials and Instrumentation James Wolffsohn Kovin Naidoo
Industry Guidelines and Ethical Considerations for Myopia Control Lyndon Jones Serge Resnikoff & Kate Gifford
Clinical Myopia Management Guidelines Kate Gifford Padmaja Sankaridurg
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Models, such as those reviewed in the accompanying IMI –
Defining and Classifying Myopia Report,39 are likely to be
efficient in predicting myopia onset, due in part at least, to
identification of a process of myopic shift already under way.
Since the predominant refractive error of young children is
usually a low degree of hyperopia, and the consensus
diagnostic criterion for myopia is 0.50 D, there is clearly a
transition stage of refractive development for those destined to
become myopic.40 The onset of the myopic trajectory is
relatively sudden compared to a subtle loss of hyperopia seen
in those who remain emmetropic.41–43 The myopic shift and
acceleration of axial elongation that precedes the onset of
myopia may be evident up to 4 years earlier and does not seem
to vary between different ethnicities.42 The high predictive
value of the models of Zadnik et al.44 and Zhang et al.45 is
therefore likely based on detection of values of refractive error
and ocular biometry during the transition phase, which depart
from those found in emmetropes of the same age.
3.3 Myopia Progression
Progression of myopic refractive error tends to be studied less
frequently than onset and prevalence in population-based
studies. However, understanding the mechanisms and risk
factors for both onset and progression, and the degree to
which they vary, are important, so the phenomena are
considered separately here. Longitudinal studies are optimal,
but are resource intensive and consequently uncommon.
Cross-sectional studies are useful when the mean refractive
errors of myopes are segregated by age.
Donovan and colleagues46 have conducted a meta-analysis
of studies reporting myopia progression rates in children of
Asian or European descent living in urban areas and corrected
with single-vision spectacles. The analysis uses data from 20
studies, 14 intervention trials, and 6 longitudinal observation
studies, to predict the progression of myopia and shows that
among existing myopes, progression rate declines with
increasing age. For example, according to the equation
provided in the study of Donovan et al.,46 progression declines
from 1.12 D/y at age 7 years to 0.50 D/y at age 12 years
among Asian children.
The progression rates presented by Donovan et al.46 arise
principally from control groups of intervention trials, which
may not be representative of the general population. For
example, parents of participants in such trials may have
enrolled them because of concern that their children’s myopia
was progressing at a rapid rate when compared with their
peers. Population-based and school-based studies tend to
report somewhat slower progression. In a rural district in
China with baseline data collected in 1998, a total of 4662
myopic (0.5 D) children with a mean age of 9.8 years
showed 0.84 D progression during 28.5 months, an average
annual progression rate of 0.35 D.47 The timing of the study
and rural habitation of this population may explain some of the
difference in myopic progression rate compared with the meta-
data reported by Donovan et al.46 The average annual
progression rate for a sample including more than 7500
myopic children aged 5 to 16 (mean, 9.3) years in Hong Kong
was reported at 0.63 D.12 Chua et al.48 have plotted annual
changes in refractive error for 928 myopic Singaporean
children of mixed ethnicity from age 7 to 11 years, stratified
by age of myopia onset. Mean progression rate at a given age is
remarkably consistent across the groups, irrespective of age of
onset. These mean progression rates are slightly slower than
those reported by Donovan et al.46 (Fig. 2).
In a large population-based study in Yongchuan District of
Chongqing City, Western China, children aged 6 to 15 years in
2006–2007 have been followed up for an average of 5.2
years.49 The authors report mean progression of 3.56 D
(average, 0.68 D/y) among myopes (0.50 D) during this
time. While presentation of the data does not allow direct
comparison, these progression rates may well be closer to
those reported by Donovan et al.46 Kim and colleagues50 have
retrospectively analyzed refractive error progression among a
population of 221 myopic South Korean children aged 3 to 9
years for an average of 11.2 years. While this was a hospital-
based study, and therefore not necessarily representative of
the population at large, the progression rate of approximately
0.50 D/y between the ages of 7 and 13 years was surprisingly
modest. Hsu and coworkers51 have reviewed a population-
based cohort in Taiwan of 3256 myopic children, of average
age 7.5 years, after 1 year and noted average progression in
the group of only 0.42 D, well below that predicted by
Donovan et al.46 Some of these children were being treated
with cycloplegics to slow myopia progression and all had
been exposed to a large-scale eye care education program,
which may explain the lower progression rate. Most recently,
Wu et al.52 have found annual progression of0.79 D among a
school-based control population of 89 myopes aged 6 and 7
years in Taiwan. This is also less than predicted by Donovan et
al.,46 but it should be noted that those in the sample
population receiving myopia treatment were excluded from
the analysis.
Further details of likely progression can be obtained from
centile progression curves. Chen et al.53 have constructed
reference age-specific centile curves of refraction from cross-
sectional population-based data from the Guangzhou Refrac-
tive Error Study in Children. However, apparent progression
among the myopes between ages of 7 and 12 years is observed
to be only approximately 0.5 to 0.6 D/y, comparatively
constant across ages, and less again than that of Donovan et
al.,46 particularly at a younger age. The implications of these
differences are not clear. Tideman et al.54 have also produced
age-specific centile curves for axial length. The relative
functionality of these curves compared to those for refractive
error is yet to be determined.
Based on the above literature review, greater myopia
progression rates are expected at younger ages (i.e., 0.50 to
1.00 D/y for 6- to 9-year-olds) than at older ages (i.e.,0.35 to
0.75 D for those older than 10 years).
FIGURE 2. Refractive shift among myopic children by age. Data from
Donovan et al.46 were digitized by using ImageJ (http://imagej.nih.gov/
ij/; provided in the public domain by the National Institutes of Health,
Bethesda, MD, USA) and replotted, and the best fit line for Asians was
taken from the equation provided in their article. Data for Chua et al.48
were obtained by averaging progression rates for given ages from their
Figure 2.
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3.4 High Myopia
One of the major ethical challenges for practitioners is accurate
identification of those at risk of becoming highly myopic or, at
the very least, of those whose myopia is progressing at an
unacceptably fast rate. Few analyses are available on this topic,
but the breakdown by Chua et al.48 probably represents the
most comprehensive data available. They have found age of
onset of myopia to be the strongest predictor of high myopia
among Singaporean children.48 As expected, duration of
myopia progression was also important in predicting high
myopia. For children with high myopia at age 11 years, there
was an 87% chance that the child became myopic at 7 years of
age or younger or had a duration of myopia progression of 4
years or more. Reports from other countries (Denmark,
Argentina, United Kingdom) reliably reproduce this observa-
tion.55–57 However, in contrast to the report by Chua and
colleagues,48 Williams et al.57 have found that age of onset only
accounts for a modest proportion (approximately 15%) of the
variance in severity of myopia.
3.5 Adult-Onset Myopia and Progression
Most of the myopia cases in one study in Britain were
considered to be late onset (16 years or older).38 Although
myopia onset past the adolescent stage of life is of clinical
interest and has shown an association with environmental
factors,58 eye care practitioners are generally more concerned
from an ethical standpoint with identifying patients at risk for
development of higher degrees of myopia, which typically
involves juvenile-onset myopia and its associated potential to
progress to sight-threatening pathology.
The prevailing perception is that myopia stabilizes in the
late teenage years.41 Certainly, annual progression in most
myopic patients slows with time and for many myopes whose
condition has progressed through the teenage years, myopia
will stabilize before they reach 20 years of age. However, there
are patients whose myopia will continue to progress through
adult years.58–60 These patients include those doing intense
near work, especially students, and those who have higher
degrees of myopia. Continued assessment of refraction and
initiation of treatment in patients showing continued progres-
sion are warranted. Higher levels of myopia will result from
continued progression through adulthood, placing these
individuals at higher risk for development of myopia-associated
pathologies.
3.6 Genetic and Environmental Risk
Risk factors for myopia onset have been identified and included
in a number of multivariate models, although to our knowledge
there is currently no comprehensive clinical model that
provides good predictive value, aside from those using
refractive or biometric information. McMonnies61 has provided
a review of risk factors for onset and progression of myopia and
produced a comprehensive table of those factors and how they
may influence the prognosis and treatment decisions for
individual patients. However, he also notes that the lack of
clinical data on the topic of risk ‘‘undermines the confidence
with which individual prognoses and clinical decisions about
interventions can be made.’’
3.6.1 Myopia Onset.
Genetics and Personal Characteristics. Heritability statis-
tics can be used to estimate the proportion of variation in a
phenotypic trait of a population that is due to genetics, and
further details can be found in the accompanying IMI – Myopia
Genetics Report.62 Heritability estimates for myopia vary from
0.11 to 0.98, the latter higher value being found among a
highly specific group of Finnish female twins aged 28 to 29
years.63,64 A meta-analysis65 places heritability at 0.71 for
refractive error, which would suggest that the majority of
influence is from genetics rather than environment.
Genome-wide association studies (GWAS)66 have demon-
strated complex inheritance of refractive error traits, with
identification of more than 150 gene loci associated with
myopia and good correlation between studies. However, the
identified loci explain a meagre percentage of the variance in
refractive error.67 For example, a genetic risk score (GRS) has
estimated that these loci explain only 0.6% and 2.3% of the
variance in refractive error at ages 7 and 15 years, respective-
ly.68 The difference between heritability from twin studies and
GWAS is known as ‘‘missing heritability’’ or the ‘‘heritability
gap’’ and is a well-known characteristic of other phenotypes
and diseases.66
While the nature versus nurture debate continues in
relation to myopia development, recognition of the importance
of gene-environment interactions in phenotypic expression has
been a significant step forward. Fan et al.68 have tested for
evidence of interactions between near work or time spent
outdoors and 39 previously identified loci from GWAS in
refractive development in a pediatric cohort. Five variants have
shown apparent interaction with near work, while neither
variant nor GRS effects were altered with time outdoors.68
The most useful clinical indicator for genetic risk short of
genetic testing is parental history of myopia. Older studies
demonstrating this association have been reviewed by Goss
and Jackson.69 Studies since that time show significant
association between number of myopic parents and incident
myopia, as summarized in a recent meta-analysis.70 Odds ratios
(ORs) ranging from 1.44 to 2.96 for having a myopic child
compared to not having a myopic child were calculated,
depending on the number of myopic parents and adjustment
for bias and missing studies.70 More recent studies confirm the
connection.27,71–76 Parental myopia has also been found to
interact with other risk factors. In one study of 1770 grade-7
Chinese students, those with close reading distances and two
myopic parents have a 26-fold higher odds for prevalent
myopia than children with reading distances of greater than 20
cm and no myopic parents.77,78 Also, unsurprisingly, parental
myopia correlates with certain ocular components, particularly
axial length.79,80
There are some further considerations around parental
myopia as a risk factor. The additive genetic portion of
phenotypic variance is smaller in younger families, reflecting
the trend for increasing environmental influences.81 The odds
of a child with two myopic parents becoming myopic is thus
different to the odds of a myopic child having two myopic
parents. In part, this stems from increased myopia prevalence,
meaning that there will likely be more children with myopia
than there are parents with myopia.43 Number of myopic
parents is a relatively gross instrument and a knowledge of
degree of myopia in family members may be a more useful
factor for predicting progression.61,82 Because of these factors,
the sensitivity of number of myopic parents in predicting
childhood myopia is correspondingly low.82,83
Rudnicka et al.37 also have found that sex differences
emerge in myopia prevalence at approximately 9 years of age
in whites and East Asians. By 18 years of age, white females
have 2.0 (95% confidence interval [CI], 1.4–2.9) times the odds
of myopia as white males, and East Asian females have 2.3 (95%
CI, 2.0–2.6) times the odds of myopia as East Asian males.
Others27,71,73 since have confirmed the propensity for greater
myopia prevalence among females. The extent to which this
influence is environmental as opposed to genetic has yet to be
determined.
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Environment. Ramamurthy and colleagues84 have reviewed
the large number of environmental risk factors for myopia.
Two key environmental influences upon myopia development
are time spent outdoors and amount of near work. The reason
time spent outdoors is protective against myopia development
remains unexplained. Although there is some evidence from
animal studies showing that high light levels or chromaticity
might be the critical factor,84 Flitcroft85 and Ngo et al.86
present a counter-argument as to why the dioptric field,
perhaps in an interaction with the high light level, is central to
protection from time spent outdoors. Xiong et al.87 have
reviewed multiple studies and suggest a clear connection
between time spent outdoors and myopia onset. However,
differentiation between consequence and causality can only be
shown in prospective randomized studies. As spending time
outdoors is an intervention to prevent or delay myopia
development, detailed description of this risk factor for myopia
onset is presented in the accompanying IMI – Interventions for
Controlling Myopia Onset and Progression Report.88
Despite some indications that near work may not be directly
related to myopia, more recent evidence suggests a clear link.89
‘‘Near work’’ has been defined and measured in a multitude of
ways across different studies (e.g., education level, duration of
continuous study time, time spent reading books for pleasure,
number of books read per week, time spent on reading and
close work, time spent indoors studying, closer working
distance, short reading distance, distance from near work,
font size, and screen-viewing activities) and is, by its nature,
difficult to quantify. Nonetheless, in a systematic review and
meta-analysis, Huang et al.89 have found more time spent on
near-work activities is associated with higher odds of myopia,
increasing by 2% for every additional diopter-hour of near work
per week. Multiple subsequent articles not included in this
meta-analysis also confirm the association of some index of
near work with development and progression of myopia, often
independently from time spent outdoors in multivariate
analyses.27,51,52,72,75,76,78,90–92 French and coworkers93 have
presented data that illustrate a strong interaction between the
effect of time spent outdoors and near work. In children with
baseline mean age of 6 years, those who spend low amounts of
time outdoors and perform high levels of near work have
dramatically increased odds of incident myopia by age 12 years
(OR, 15.9; 95% CI, 3.5–73.4) as compared with those who
spend high amounts of time outdoors and low amount of time
involved in near work.
Both country and location of residency (urban versus rural)
of an individual are associated with the likelihood of myopia.
Rose et al.94 have found that the prevalence of myopia in 6- to
7-year-old children of Chinese ethnicity is significantly lower in
Sydney, Australia (3.3%) than Singapore (29.1%). In their large
meta-analysis of childhood myopia prevalence from popula-
tion-based surveys, Rudnicka et al.37 have shown striking
differences in prevalence among school-aged children of
Eastern Chinese ancestry, based on their country of residence
(Fig. 3). Among South Asian children living in Australia,
England, or Singapore, myopia was five times as likely
compared to those living in India or Nepal. There was no
apparent difference in prevalence of myopia among white
children in studies from Europe, United States, and Oceania.
The authors also determined that children from urban
environments have 2.6 (95% CI, 1.8–3.9) times higher odds of
myopia than those from rural environments.37 Consistent with
this finding, population density, home size, and housing type
are also significantly associated with refractive error and axial
length.95,96 The mediating factors for all of the environmental
effects are likely to be a combination of education, near work,
and time spent outdoors.
Physical attributes (height, weight, and body mass in-
dex),29,97,98 prenatal history,99 birth season,100,101 intelli-
gence,102,103 and socioeconomic status27,104,105 have all been
linked to the likelihood of myopia, with varying strengths of
association.
Binocular Vision. It has long been postulated that myopia
onset and progression may be related to dysfunctional
accommodation and convergence.106 An elevated accommo-
dation-convergence/accommodation (AC/A) ratio has been
observed before the onset of myopia.44,107 In a large, ethnically
diverse group of children followed up for an extensive period
of time, Mutti and colleagues108 have found the AC/A ratios of
those who become myopic begin to increase approximately 4
years before myopia diagnosis, continue increasing until
diagnosis, and then plateau at a level higher than those who
remain emmetropic.
Another feature of accommodation that has been observed
is that measured lag of accommodation is larger among myopes
than nonmyopes.109,110 It was thought that the presence of lag
before onset may produce hyperopic retinal defocus, stimulat-
ing myopia onset. However, this effect only appears at the time
of onset, not before, and does not seem to impact progres-
sion.108,111 An aspect of accommodative lag worthy of mention
is that spurious measurement of accommodative error is well
documented.112–114 So-called lag may be substantially a
function of the measurement technique, where depth of focus
and increasing negative spherical aberration with accommo-
dation and developing myopia are not taken into account.
The shift in refraction (in terms of a reduction in hyperopia)
observed in those who will become myopic compared to those
who remain emmetropic begins several years before diagnosis.
Changes to the AC/A ratio merely seem to parallel such
changes. Accommodative lag does not seem to appear until
myopia onset.115 Thus, while binocular vision attributes are an
interesting research adjacency in the onset and development of
myopia, from our current knowledge they do not seem to add
any additional benefit in risk assessment over refraction and
biometric parameters, genetics, or environmental effects.
3.6.2 Myopia Progression. Compared with onset, there is
a lower volume of literature describing risk of progression for
existing myopes other than age and initial refractive error.
Some studies have looked at group progression, including
emmetropes and hyperopes as well as myopes in their
analyses, which does not allow specific interpretation regard-
ing progression among myopes.
FIGURE 3. Modeled prevalence of myopia by age for East Asians by
selected country of residence from a systematic review and quantita-
tive meta-analysis adjusted to the year 2005 (except for Mongolia,
which is 2003). Graph created from data in Table 4 of Rudnicka et al.37
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Genetics and Personal Characteristics. Donovan et al.46
report that myopia in European children progresses more
slowly on average than in Asians (0.55 D/y and 0.82 D/y,
respectively, at mean age of 9.3 years), although age-specific
progression data by baseline age for Europeans in their analysis
are derived from a single article. For studies conducted in
somewhat homogeneous Western societies, the analysis of
Mutti et al.42 supports the ethnic differences in progression
rates found in the study by Donovan and colleagues,46
although French et al.116 did not establish significance of an
ethnicity effect. Gwiazda and colleagues117 have looked at risk
factors for high myopia, which can be considered a corollary of
fast progression. Reporting on an ethnically diverse population
of children aged 6 to 11 years with initial myopia between
4.50 and 1.25 D at four sites within the United States, they
did not find an effect of ethnicity on progression rates.
Environment is also likely to play a role in myopic progression
rates, which may be inferred from higher degrees of myopia
among Asian children living in Asia compared to those living in
Western societies; however, a thorough review of differences
in progression rates between ethnically similar populations in
different environments does not seem to have been undertak-
en.
In their study, Gwiazda et al.117 found that the number of
myopic parents is a risk factor for high myopia. Some studies
support the proposition that parental myopia is associated
with faster progression rates, where others do not.91,118,119
Females show faster progression than males according to
Donovan et al.46 (0.80 D/y and 0.71 D/y, respectively, at
mean age 8.8 years) and Zhou et al.49 (OR, 1.45; 95% CI, 1.12–
1.84). However, such a difference is not evident in the study of
Gwiazda et al.117
Environment. In their meta-analysis, Xiong et al.87 report
that outdoor time is not effective in slowing progression in eyes
that are already myopic. However, a more recent prospective
study52 suggests that outdoor time does have a protective effect
on rate of progression. Subsequent cohort studies51,74,118,120
yield mixed results. Support for the protective effect of time
spent outdoors on myopia progression may be inferred from
numerous studies that have found a seasonal variation in myopia
progression;121–123 see the accompanying Interventions for
Controlling Myopia Onset and Progression Report.88
Many of the same environmental factors that are linked to the
incidence or prevalence of myopia are also related to
progression. Multiple articles link near work, with various
descriptors of activity, to myopia progression.51,52,72,74,91,119,120
Other associations include urbanization and increasing family
income.90,91
Binocular Vision. Two studies that have considered
binocular vision effects as part of the treatment protocol
(esophoria or low lag of accommodation) have had good
success, suggesting that some aspect of binocular function may
be a risk factor for progression.124,125
3.7 Summary of Findings on Risk Factors
The observations reported above present an unambiguous
message. The younger the age of onset of myopia, the greater
the likelihood that a child will experience progression to
vision-threatening levels of myopia. Practitioners and parents
should be active in addressing both myopia onset and
progression at as young an age as possible. No formal
procedures have been identified that recognize those at risk
of myopia onset before the triggering of the steady progression
in refractive error that ultimately leads to myopia diagnosis.
However, it is clear, for example, that Chinese children living in
urban regions of Asia, who are immersed in an intensive
education environment and have two myopic parents, have a
much greater risk for onset and development of significant
myopia than a Caucasian living in a rural environment in
Australia with no myopic parents. Not all children who are
young at myopia onset will experience progression to high
myopia, but age of onset is the current best determinant for
identifying children at risk of progression. While noting the
risk of high myopia is greatest in those with early onset,
practitioners should also be cognizant that the condition of
some individuals with later onset (say 11 years or older) may
also progress to higher degrees of myopia, where the rate of
progression is high. Practitioners should be vigilant in
identifying and treating those at risk of rapid progression,
regardless of age of onset.
4. SUBCOMMITTEES AND THEIR REPORT FOCUS AND
ADVANCEMENTS
4.1 IMI – Defining and Classifying Myopia Report39
Myopia has been the topic of scientific study for more than 400
years, but it is only more recently that it has been recognized as
a serious public health issue, owing to its being a significant
cause of visual loss and a risk factor for a range of pathologic
ocular conditions. Its prevalence is increasing on a global basis
and has reached epidemic levels in much of Asia. Myopia has
been defined in a wide variety of ways in the past, such as
based on its assumed etiology, age of onset, progression rate,
degree of myopia (in diopters), and structural complications.
This has led to a confusing accumulation of terms. Hence this
subcommittee’s aim was to provide a standardized set of
terminology, definitions, and thresholds of myopia and its main
ocular complications. A critical review of current terminology
and choice of myopia thresholds was undertaken to ensure
that the proposed standards are appropriate for clinical
research purposes, relevant to the underlying biology of
myopia, acceptable to researchers in the field, and useful for
developing health policy. It is recommended that the many
descriptive terms of myopia be consolidated into the following
descriptive categories:
Myopia: A refractive error in which rays of light entering the
eye parallel to the optic axis are brought to a focus in front
of the retina when ocular accommodation is relaxed. This
usually results from the eyeball being too long from front to
back, but can be caused by an overly curved cornea, a lens
with increased optical power, or both. It is also called
nearsightedness.
With qualifying terms:
Axial Myopia: A myopic refractive state that can be
attributed to excessive axial elongation.
Refractive Myopia: A myopic refractive state that can be
attributed to changes in the structure or location of the
image-forming structures of the eye (i.e., the cornea and
lens).
Secondary Myopia: A myopic refractive state for which a
single, specific cause (e.g., drug, corneal disease, or
systemic clinical syndrome) can be identified that is not a
recognized population risk factor for myopia development.
It was also recommended that in quantitative contexts,
myopia should always be treated as a negative value and that
mathematical comparison symbols be used in their strict
mathematical sense.
To provide a framework for research into myopia preven-
tion, the condition of ‘‘premyopia’’ is defined.
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Premyopia: A refractive state of an eye of þ0.75 D and
>0.50 D in children where a combination of baseline
refraction, age, and other quantifiable risk factors provides a
sufficient likelihood of the future development of myopia to
merit preventative interventions.
As a quantitative trait it is recommended that myopia be
divided into myopia (i.e., all myopia), low myopia, and high
myopia as based on the current consensus of publications:
Myopia: A condition in which the spherical equivalent
refractive error of an eye is 0.5 D when ocular
accommodation is relaxed.
Low Myopia: A condition in which the spherical equivalent
refractive error of an eye is 0.5 D and >6.00 D when
ocular accommodation is relaxed.
High Myopia: A condition in which the spherical equivalent
refractive error of an eye is 6.00 D when ocular
accommodation is relaxed.
Although even low levels of myopia are associated with an
increased risk of developing pathologic conditions such as
myopia maculopathy and having a retinal detachment,
‘‘pathologic myopia’’ is proposed as the categorical term for
the adverse, structural complications of myopia.
Pathological Myopia: Excessive axial elongation associated
with myopia that leads to structural changes in the posterior
segment of the eye (including posterior staphyloma, myopic
maculopathy, and high myopia–associated optic neuropa-
thy) and that can lead to loss of best-corrected visual acuity.
A clinical classification is also proposed to encompass the
scope of such structural complications.
4.2 IMI – Experimental Models of
Emmetropization and Myopia Report126
Much of our current understanding of characteristics and
mechanisms of postnatal eye growth and the development of
myopia has come from detailed experimental studies using
animal models. These models use a wide range of species, from
primates to invertebrates, and include macaque and marmoset
monkeys, tree shrews, guinea pigs, mice, chickens, fish, and
squids. Considering that these phylogenetically wide-ranging
species all possess visually guided eye growth despite
differences in ecology, ocular anatomy, visual function, and
visual acuity, this supports the hypothesis that visually guided
eye growth is an evolutionarily conserved process found in
camera-type eyes. Each species provides unique experimental
advantages to study the mechanisms of visually guided eye
growth and the key signalling pathways that regulate refractive
eye development across species; however, anatomic and
physiological differences must be taken into account when
interpreting and translating results to humans.
The report summarizes the anatomic similarities and
differences between the eyes of the principal experimental
species used for studies of emmetropization and myopia.
Surveying more than 800 published reports on the changes in
eye growth and refractive state in response to experimental
manipulations of visual conditions, the report offers a summary
of the evidence supporting the role of vision in eye
development and the mechanisms that underlie the visual
regulation of eye growth and emmetropization development.
Also discussed are the key operating characteristics of
experimental emmetropization to experimentally imposed
retinal defocus including local retinal mechanisms controlling
regional eye growth, the spatial and temporal integration of
visual signals, the impact of simultaneous competing defocus
signals, the relationships of various ocular circadian rhythms to
induced changes in eye growth, and the critical periods for
visual experience–invoked myopia. Studies of the characteris-
tics of the visual signals affecting eye growth are also reviewed
and discussed, including the intensity of ambient illumination,
the spectral composition of light, longitudinal chromatic
aberration, higher-order monochromatic aberrations, and
astigmatism. The report reviews the biochemistry of refractive
error development, including the roles of various retinal
neurotransmitters, neuromodulators, and growth promotors
such as dopamine, vasoactive intestinal peptide, melanopsin,
glucagon, and insulin, and nitric oxide. Pharmacologic studies
of the mechanisms of emmetropization and myopia are
discussed including the effects of cholinergic, GABAergic,
and adenosine antagonistic drugs and drugs affecting nitric
oxide and neuropeptides. Finally, the article reviews the
molecular biology of gene expression in the eye and retina
and possible gene-environment interactions.
The report reviews and summarizes several confirmed
findings from animal models that have provided important
proofs of concept that helped to transform treatment strategies
for myopia control. These findings include the eye’s ability to
detect the sign of retinal defocus and undergo compensatory
growth, the local retinal control of eye growth, regulatory
changes in choroidal thickness, and the identification of
biochemical signal cascades regulating postnatal eye growth
and refractive state. Experimental animal models continue to
provide new insights into the cellular and molecular mecha-
nisms of eye growth control, including the identification of
potential new targets for drug development and future
treatments needed to stem the increasing prevalence of
myopia and the vision-threatening conditions associated with
this disease.
4.3 IMI – Myopia Genetics Report62
Like other complex traits, myopia has benefitted enormously
from the dramatic improvements in DNA technologies and
significant reduction in costs for genotyping during the last
decade. The IMI – Myopia Genetics Report summarizes the
developments in gene identification for refractive error and
myopia, and addresses their implications for molecular
pathways. An extensive literature search identified almost
200 genetic loci that have been reported for refractive error,
myopia, or axial length, and many overlap between these
endophenotypes. Risk variants have mostly been identified
outside the protein coding regions, and by themselves carry a
low risk. Nevertheless, totalling all genetic risk variants in a
polygenic risk score shows that those with a high genetic load
are >40 times more likely to become myopic, and high myopes
and high hyperopes can be separated by their genetic score.
The most significant contribution of the current gene
dissection is the insights into the molecular machinery
underlying eye growth. Functions of the annotated genes
include retinal cell physiology, light processing, glutamate
receptor signalling, extracellular matrix modulation, anterior
segment morphology, but also posttranscriptional regulation
indicating control of gene expression at the RNA level. In silico
and in vitro experiments have shown that all cell types in the
retina, but also RPE, vascular bed, and connective tissue are
sites of gene expression. This implies that the retinal signalling
cascade responding to a visual trigger and leading to eye
growth involves a complex network of molecules from many
different cells and tissues. Another lesson learned from the
genetic studies is that most genes are not eye specific and have
a plethora of effects outside of the eye. A fair number of genes
for common myopia are involved in a wide range of syndromes,
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including neurodegenerative and connective tissue disorders.
How this broad spectrum of gene functions leads to scleral
remodelling and an increase of axial length remains intriguing.
Addressing this ‘‘black box’’ requires taking myopia molecular
genetics to the next level: to explore new high-throughput,
wide coverage genotyping assays; determine the protein
function and the elements that regulate gene expression;
investigate how DNA, proteins, and the environment interact
to determine eye size; and create possibilities for storage and
reuse of massive genomic data. The forecast of understanding
and solving myopia makes these challenges worth taking.
4.4 IMI – Interventions for Controlling Myopia
Onset and Progression Report88
This report examines the evidence basis for various interven-
tions in current use for controlling myopia progression in
children, organized under the categories of optical, pharmaco-
logic, environmental (behavioral), and surgical interventions
(aimed at stabilizing highly myopic eyes). There is equivocal
evidence concerning whether single-vision spectacles cause
faster myopic progression than soft contact lenses, but any
difference is likely to be clinically irrelevant. Undercorrection
is still adopted as a myopia control strategy by some
practitioners, yet some but not all clinical trials indicate this
strategy has no clinically significant benefit in slowing myopia.
Single-vision spectacle lenses designed to alter peripheral
defocus had only a small treatment effect, of less than 14%
reduction in myopia progression. The treatment effects on
myopia progression of bifocal and progressive addition
spectacles tend to be larger, although variable and questioned
in terms of clinical significance in some cases (6%–51%).
Overall, single-vision contact lenses, whether soft or rigid,
seem to have little effect on myopia progression, in contrast to
significant treatment effects with contact lenses that impose
multifocality. Center-distance multifocal lenses have been used
off-label successfully, demonstrating a sample size–weighted
average of 38%, slowing both myopia progression and axial
elongation, although these two assessment elements did not
always correspond tightly. Orthokeratology has also proven to
be effective in slowing axial length elongation, by between
30% to 55%.
Pharmacologic myopia control trials have principally used
atropine, although other muscarinic antagonists such as M1
selective pirenzepine, ocular hypotensive agents including
topical timolol (a nonselective b-adrenergic antagonist), and
oral 7-methylxanthine, an adenosine antagonist, have also
undergone trial. Although the reduction in myopia progression
seems to be higher with 1% atropine (around 60%–80%), more
recent atropine studies use much lower doses (e.g., 0.01%),
with a reduced effect on refractive error retardation (around
45%) and no apparent effect of axial length compared to
historical controls, but with fewer side effects and apparent
rebound after discontinuation.
Time outdoors appears to be more effective in preventing
incident myopia than slowing progression of existing myopia.
However, the evidence for vitamin D levels being related to
myopic control is weak. Seasonal trends in myopia progression
have also been interpreted as indirect evidence of outdoor
effects on myopia progression, based on observed faster
myopia progression during the darker winter than the brighter
summer months. In one study, every additional hour of outdoor
time per week has been found to reduce the risk of developing
myopia by 2%. In another study, the time children spend
engaged in near work outside of school and time spent outdoor
were not found to be related, as might be expected.
Deployment of wearable technologies in place of question-
naires as study tools may help to resolve apparent inconsis-
tencies and unresolved questions, including whether the
quality of indoor lighting is important.
4.5 IMI – Clinical Myopia Control Trials and
Instrumentation Report127
Clinical trials on myopia control conducted to date were
reviewed to inform a consensus on best practice in the design
of clinical trials to assess the effectiveness of treatments and
the impact on patients. As myopia control interventions will be
applied for multiple years throughout the time during which
myopia is progressing, and treatment effects have been shown
to often reduce after an initial period, it is important that
clinical trials evaluate efficacy over a long period (3 years being
the recommendation) to ensure continued efficacy beyond any
initial treatment effect. Assessment of rebound should also be
considered, with a minimum recommended period of 1 year
due to seasonal effects. Typical inclusion criteria are cyclople-
gic spherical or spherical equivalent myopia of at least0.75 D;
astigmatism  1.00 D; anisometropia  1.50 D; ages 6 to 12
years; and 20/20 (0.0 logMAR) minimum visual acuity.
Exclusion criteria typically are previous rigid contact lens
wear; history of previous myopia control treatment; ocular
pathology; binocular vision anomaly; medications that may
affect pupil size, accommodation, or have an impact on ocular
surface; and systemic disease that may affect vision, vision
development, or the treatment modality. Appropriate control
group selection depends on the intervention being studied, but
often myopia control studies cannot be fully masked. Studies
with no control group are unable to demonstrate treatment
efficacy; as the rate of myopia progression decreases naturally
with age and has seasonal variation, it is not possible to
distinguish between naturally declining progression and
reduced progression attributable to the treatment, without a
simultaneously conducted control group. Randomization
should be applied to treatment allocation, and stratification
by key factors known to influence myopia progression (such as
age and race/ethnicity) should be considered. Ocular health,
including a slit lamp examination and baseline/periodic dilated
fundus examination, along with standardized adverse event
reporting, should also be embedded in the trial protocol.
Binocular vision associations in myopia control treatments
have also been found, so should be investigated at baseline and
periodic intervals during the study. Other safety-related
assessments include visual acuity and dysphotopsia. Finally,
there is not a specific minimum percentage reduction in
myopia progression that has been published for a treatment
effect to be considered clinically meaningful; any such
percentage reduction threshold could theoretically vary with
multiple other factors, including duration of treatment, sample
population, and study design considerations. Sample size
estimations based on currently available measurement variabil-
ity data are provided.
Outcome measures were classified as primary, secondary,
and exploratory. Primary outcome measures are refractive
error (ideally assessed objectively with autorefraction of the
eye cyclopleged in optical intervention studies with 1%
tropicamide) or axial length (ideally measured with noncontact
interferometry) or both. Secondary outcome measures focus
on patient-reported outcomes (usually assessed by question-
naire and can include the parent’s/guardian’s experience as
well as the patient’s) and treatment compliance (ideally in real
time, such as with text messaging responses or wearable
sensors connected to data loggers). Exploratory outcome
measures are particularly useful in trying to understand the
mechanism of action and associated factors. These include
peripheral refraction (such as measured with autorefractors or
wavefront aberrometers), accommodative changes (including
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accommodative lag and dynamics), ocular alignment, pupil
size, outdoor activity/lighting levels, anterior and posterior
segment structural changes (typically imaged with Scheimpflug
imaging, optical coherence tomography, and retinal photogra-
phy with a particular interest in choroidal thickness changes),
and tissue biomechanics (of the sclera and cornea).
4.6 IMI – Industry Guidelines and Ethical
Considerations for Myopia Control Report128
The aim of this subcommittee was to discuss guidelines and
ethical considerations associated with the development and
prescription of treatments intended for myopia control. A
critical review of published articles and guidance documents
was undertaken, with a view to carefully consider the ethical
standards associated with the investigation, development,
registration, marketing, prescription, and use of myopia
control treatments.
From an ethical standpoint, deciding whether to implement
a myopia control strategy represents a classical medical risk
versus benefit ratio. A principal motivation for slowing myopia
progression is based on the premise that limiting myopia
progression reduces risk of the development of vision-
threatening disease in later life. However, conclusive evidence
that this is the case is unlikely to be available for decades.
Nonetheless, if this assumption is correct, then the benefits
could be substantial, given the clear relationship between
myopia-related ocular pathology and the degree of myopia.
Thus, the risk-benefit analysis must take account of the
outcomes arising from nonintervention in deciding if imple-
mentation of a myopia control strategy with an individual
patient is warranted. Other factors to consider include the
known improvements in quality-of-life issues arising from the
use of corrective devices; adults with pathologic myopia and
associated visual impairment report significant social and
emotional impacts and reduced life satisfaction. Additional
factors that must be accounted for in the decision to undertake
myopia control include the regulatory status of the treatment
being considered, availability of the treatment, access to
appropriate eye care services, and pricing and convenience
of the treatment, which are all potential barriers to accessing
the myopia control treatment being considered.
These considerations place a burden of responsibility on
the practitioner to be fully cognizant of the risks for the patient
of developing different levels of myopia, the implications that
progression to higher levels of myopia may have, the likely
benefits of treatment, the side effects of treatment and other
associated factors, so as to provide appropriate advice and
care.
Researchers and clinicians often partner with companies to
conduct myopia control studies. However, there is a risk for
these partnerships to introduce bias, and practitioners should
be aware of the importance of evaluating any real (or
perceived) conflict of interest when recommending a manage-
ment plan for myopia control. The interactions between
researchers, practitioners, and manufacturers of myopia
control treatments should meet the highest possible standards
of integrity and transparency and must be declared in the
reporting of the results obtained. Relationships between
clinicians and patients should not be compromised by
commercial or other interests that could subvert the principle
that the interests of patients are of primary concern.
Most myopia control treatments are currently off-label in
many countries. Most regulatory bodies do not restrict
practitioners from discussing off-label treatment uses with
their patients. However, given that patients and their families
generally assume that a treatment prescribed by their clinician
has been proven safe and effective and is supported by
scientific evidence, it is recommended that practitioners
ensure that a formal informed consent process is adopted, to
ensure that the patient (and parents/guardians in some cases)
is aware of the risks, benefits, and alternatives for any myopia
control treatment discussed.
Regulatory bodies, manufacturers, academics, practitioners,
and patients are all stakeholders and play an important role in
ensuring the appropriate prescribing and success of myopia
control treatments. Approval of a treatment by a regulatory
body relies on the risk-benefit assessment and is informed by
science, medicine, policy, and judgment, in accordance with
applicable legal and regulatory standards. Manufacturers have a
large part to play in the ethical decisions around the
practitioner’s prescribing of myopia control treatments by
ensuring that the discussion of the efficacy of a treatment is
appropriately reported and that the treatments are manufac-
tured by using rigorous methods to ensure their quality.
Academics have an important role in disseminating scientific
information related to myopia control treatments, which is
typically undertaken in the form of peer-reviewed journal
articles, in addition to abstracts and presentations at major
scientific conferences. Practitioners have a responsibility to
care for their patients by recommending myopia control
treatments using evidence-based practice. With a condition as
multifactorial and individual as myopia, this means using
published evidence along with clinical judgment to determine
the best course of action for the young myopic patient. Finally,
patients should be well informed about the nature of the
product’s marketing authorization status for the intended use
and, in case of off-label/unlicensed treatments, that the risks
associated with the treatment might be unknown. Such
information should be provided in a neutral, balanced, and
nonbiased way by the practitioner and be accompanied by
easily accessible online and printed information.
Undertaking myopia control treatment in minors creates an
ethical challenge for a wide variety of stakeholders. Regulatory
bodies, manufacturers, academics, and clinicians all share an
ethical responsibility to ensure that the products used for
myopia control are safe and efficacious and that patients
understand the benefits and potential risks of such products.
4.7 IMI – Clinical Myopia Management Guidelines
Report129
This report draws on the evidence basis outlined principally in
the IMI – Interventions for Controlling Myopia Onset and
Progression Report88 for establishing clinical guidelines to
inform the management of the progressing myopic patient.
This includes risk factor identification from the assessment of
refractive error, binocular visual function, parental refraction,
and visual environment (such as educational intensity and time
spent outdoors) at around ages 6 to 11 years; discussion of the
prospect of developing myopia and the associated risks, along
with treatment option efficacy, risks, and additional correction
benefits with the parents/guardians and the patient in lay
terms; setting realistic expectations; gaining informed consent;
agreement of compliance and a follow-up schedule; and off-
label considerations. Key baseline examination procedures
include a detailed ocular and general health history (including
parental refractive error, myopia onset, any previous correc-
tion/treatment, and time spent outdoors/doing detailed near
work), subjective refraction (objective refraction following
cycloplegia when indicated), visual acuity, binocular vision
(principally vergence) and accommodation (particularly lag
and amplitude) assessment, corneal topography (if considering
orthokeratology), slit lamp biomicroscopy of the anterior eye
(including signs of dry eye disease), intraocular pressure
measurement (if considering pharmaceutical treatment), dilat-
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ed fundus examination, and ideally noncontact axial length
measurement. Exploratory tests that may be used clinically in
future include uncorrected relative peripheral refraction,
ocular aberrations, pupil size, subfoveal choroidal thickness,
and wearable devices to track visual habits and the environ-
ment. Treatment strategies need to be agreed upon in
conjunction with the patient and parents/guardians with
aspects such as their risks/benefits, the patient’s lifestyle, and
ease of compliance taken into account. Myopia ‘‘calculators’’
can be useful to visualize the average potential outcome based
on research studies, but it must be noted that projections are
based on carefully selected subjects examined for between 2
and 5 years only. Owing to the inherent risks of any treatment
(contact lens, pharmaceuticals), treatment is not generally
advisable until the myopia is visually significant (0.50 D to
0.75 D), and baseline refractive error will determine the
availability and potential effectivity of treatment. Although
undercorrecting myopia is still practiced in some countries,
most robust studies show it to either have no effect or increase
the rate of myopia progression, hence children should be
encouraged to wear their myopic correction full time. Children
should not be prevented from participating in near-work
activity, but regular breaks and fixation changes from intense
near work should be encouraged, along with sufficient time
(8–15 hours/week) outdoors. Treatments are likely to be most
effective at younger ages, when rapid progression is underway;
the efficacy of some treatments may wane after the first 6
months to 2 years of treatment and the effects could rebound
after cessation (particularly with higher-dose pharmaceuticals).
The guidelines recommend 6 monthly follow-ups to monitor
safety and efficacy of the myopia control treatment, performing
the same tests as at baseline, but with cycloplegic refraction
and dilated fundus examination conducted annually or on
indication. The future research directions of myopia interven-
tions and treatments are discussed, along with the provision of
clinical references, resources, and recommendations for
continuing professional education in this growing area of
clinical practice.
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APPENDIX
TABLE A1. Consolidated Acronymn/Abbreviation List for IMI – Reports
Abbreviation Definition
7-MX 7-Methylxanthine
AC/A Accommodative convergence to accommodation
ACES Anyang Childhood Eye Study
Add Bifocal addition
ADTN (þ/)-2-Amino-6,7-dihydroxy-1,2,3,4-
tetrahydronaphthalene
AF Retinal autofluorescence
AL Axial length
ALSPAC Avon Longitudinal Study of Parents and Children
ANSES French Agency for Food, Environmental and
Occupational Health & Safety
APLP2 Amyloid-like protein-2
AREDS Age-Related Eye Disease Study
ATOM Atropine in the treatment of myopia
atRA All-trans-retinoic acid
b Regression coefficient
BAK Benzalkonium chloride
BF Bifocal
BHVI Brien Holden Vision Institute
BMES Blue Mountain Eye Study
BMP Bone morphogenic protein
BS British standard
C Control group
CA repeats Cytosine-adenine repeats
cAMP Cyclic adenosine monophosphate
CCL Collagen cross-linking
CE Conformite´ Europe´enne
cGMP Cyclic guanosine monophosphate
CI Confidence interval
CLEERE Collaborative Longitudinal Evaluation of
Ethnicity and Refractive Error
CNV Choroidal neovascularization
COI Conflict of interest
COMET Correction of Myopia Evaluation Trial
CPD Continuing professional development
CREAM Consortium for Refractive Error and Myopia
D Dioptres
DA Dopamine
DFP Diisopropylfluorophosphate
ECM Extracellular matrix
ECP Eye care practitioners
EN European standard
eNOS Endothelial nitric oxide synthase
ENSLI Enkephalin-, neurotensin-, and somatostatin-like
immunoreactive amacrine cells
EOM Early onset myopia
Eso Esophoria
EU European Union
FA Fluorescein angiography
FC Full correction
FDA Food and Drug Administration
FDM Form deprivation myopia
FGF Fibroblast growth factor
FRD Foveal RD
FU Follow-up
GABA Gamma-amminobutyric acid
GAG Glycosaminoglycan
GCP Good clinical practice
GCTA Genome-wide complex trait analysis
GEWIS Genome-environment-wide interaction studies
GLP Good laboratory practice
TABLE A1. Continued
Abbreviation Definition
GLP-1 Glucagon-like peptide-1
GMP Good manufacturing practice
GOAL Guangzhou Outdoor Activity Longitudinal Study
GP Gas permeable rigid contact lens
GRS Genetic risk score
GWAS Genome Wide Association Studies
GxE Gene-environment interaction
HCP Healthcare professional
HM-PRO High myopia-partial reduction orthokeratology
HOA Higher-order aberrations
Hrs Hours
ICD International Classification of Disease
ICG Indocyanine green angiography
IOP Intraocular pressure
IRB Institutional review board
ISO International Organization for Standardization
KORA Cooperative Health Research in the Region
Augsburg
LCA Longitudinal chromatic aberration
L-DOPA Levodopa (L -3,4-dihydroxyphenylalanine)
LED Llight emitting diode
LIH Lens induced hyperopia
LIM Lens induced myopia
L-NAME N omega-nitro-L-arginine methyl ester (NOS
inhibitor)
L-NIO N5-(1-Iminoethyl)-L-ornithine (NOS inhibitor)
L-NMMA NG-methyl-L-arginine acetate (NOS inhibitor)
LogMAR Logarithm minimum angle of resolution
LOM Late onset myopia
LORIC Longitudinal orthokeratology research in
children
MC Myopia control
META-PM Meta-Analysis for Pathologic Myopia Study
Group
MF Multifocal
MFSCL Multifocal soft contact lens
MM Myopic maculopathy
mm Millimetres
MMD Myopic macular degeneration
MMP Matrix metalloprotease
MR Mendelian randomization
MRI Magnetic resonance image
MT Muscarinic toxin
MTF Modulation transfer function
MX Methylxanthine
NA Not applicable
nNOS Neuronal nitric oxide synthase
NO Nitric oxide
NOS Nitric oxidase synthase
NP Not provided
N-PLA Nx-propyl-L-arginine (NOS inhibitor)
OCT Ocular coherence tomography
OK Orthokeratology
OLSM Orinda Longitudinal Study of Myopia
OMIM Online Mendelian Inheritance in Man database
OR Odds ratio
PAL Progressive addition spectacle lenses
PA-PAL Peripheral aspherized, progressive addition
spectacle
PG Proteoglycan
PMA Premarket approval
PMDA Pharmaceuticals and Medical Devices Agency
PPG Pre-proglucagon
PR Partial reduction
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TABLE A1. Continued
Abbreviation Definition
PRO Patient reported outcomes
PSR Posterior scleral reinforcement
QOL Quality of life
QTL Quantitative trait locus
r Correlation coefficient
RA Retinoic acid
RAAB Rapid assessment of avoidable blindness
RALDH2 Retinaldehyde dehydrogenase 2
RAR Retinoic acid receptor
RCT Randomized clinical trial/Randomized controlled
trial
RCUK Research Council of the United Kingdom
ROC Recess outside the classroom
ROMIO Retardation of myopia in orthokeratology
RPE Retinal pigment epithelium
SAVES Sydney Adolescent Vascular and Eye Study
SCL Soft contact lenses
SCN Suprachiasmatic nucleus
SCORM Singapore Cohort Study of Risk Factors for
Myopia
SER Spherical equivalent refraction
SMS Sydney Myopia Study
SNP Single nucleotide polymorphism
Specs Spectacles
SSGAC Social Science Genetic Association Consortium
SSI Injection-based scleral strengthening
STARS Strabismus, Amblyopia and Refractive Error
Study in Young Singaporean Children
SV Single vision
TGF Transforming growth factor
TIMP Tissue inhibitor of metalloprotease
TO-SEE Toric orthokeratology slowing eye elongation
UC Under-corrected
UK United Kingdom
USA United States
UV Ultraviolet
VEGF Vascular endothelial growth factor
VIP Vasoactive intestinal peptide
WES Whole-exome sequencing
WGS Whole-genome sequencing
WHO World Health Organization
Yr Year/years
DBF Bifocal with base-in prism
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